Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis

פריטים דומים

• Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
  מאת: D. E. Karateev, et al.
  יצא לאור: (2016-09-01)
• What do we know about the possibility of predicting the potential efficacy and safety of methotrexate, by measuring the concentration of its metabolites in rheumatoid arthritis?
  מאת: G. I. Gridneva, et al.
  יצא לאור: (2020-09-01)
• Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
  מאת: I. V. Menshikova, et al.
  יצא לאור: (2019-05-01)
• Polyarteritis nodosa is an unforeseen borderline paradoxical adverse reaction in a female patient with rheumatoid arthritis treated with tofacitinib
  מאת: Yu. V. Muraviev, et al.
  יצא לאור: (2019-09-01)
• The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
  מאת: Yu. V. Muravyev, et al.
  יצא לאור: (2018-09-01)